Summary: In a randomised trial in type 2 diabetes, the GLP-1 analogue Ebenatide improved HbA1c, time in range, the triglyceride-glucose index, weight, and waist-to-height ratio over 24 weeks versus placebo, with benefits sustained to 52 weeks and only gastrointestinal side effects.
PICO Summary
| Element | Detail |
|---|---|
| Population | 78 adults with type 2 diabetes (76 completed), randomised 2:1. |
| Intervention | Ebenatide (a GLP-1 analogue) for 52 weeks (n=52), with continuous glucose monitoring and body-composition analysis. |
| Comparison | Placebo for 24 weeks then Ebenatide for 28 weeks (n=24). |
| Outcome | Vs baseline, Ebenatide lowered HbA1c, mean glucose, time-above-range, and glucose SD and raised time-in-range at weeks 24 and 52; TyG fell by week 52. Vs placebo, greater HbA1c and time-above-range improvement at week 24 but no difference at week 52. Weight, BMI, body fat, and waist-to-height ratio fell. Adverse events were gastrointestinal only. |
Ebenatide in Type 2 Diabetes
RCT · type 2 diabetes · 52 weeks
Ebenatide cut HbA1c by about 1.2% and nearly doubled time in range at 24 weeks versus placebo, with weight and waist-to-height ratio falling. A small single-centre trial confirming a GLP-1 class effect.
Expert Commentary
This is a positive trial that mostly confirms a class effect rather than revealing anything novel: Ebenatide, a PEGylated exenatide developed and used largely in China, does what GLP-1 receptor agonists reliably do, improving glycaemia, time in range, weight, and body composition, with the expected gastrointestinal tolerability. I read it as reassuring evidence that the benefits of the class extend across molecules and populations. Two honest caveats shape how much I lean on it. The design is partly within-group, the between-group advantage over placebo was significant at 24 weeks but had narrowed to non-significance by 52 weeks once the placebo arm crossed over to active drug, which is expected but worth stating plainly. And with 78 participants at a single centre this is a modest study without cardiovascular-outcome data for this specific agent. Can I use this with my patients? Not directly, since Ebenatide is not available in most countries outside China, but it reinforces my confidence in prescribing the GLP-1 class broadly and in using time-in-range alongside HbA1c as a target. Where the better-studied agents are available I would still choose those.
References
Xu CL, Kong XC, Liu XM, Xu XH, Liu BL, Ma JH. Effect of Ebenatide on glycemic metabolism and body fat in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2025;16:1622526. doi:10.3389/fendo.2025.1622526